From clinical validation to global market leader
Bio Vitos Pharma addresses three of the world’s most common deficiency diseases with a patented portfolio of well-tolerated drug candidates designed to minimize adverse effects.
Groundbreaking heart failure (CHF) treatment
SUCCIFER®
Status
Pilot study completed and patented in 26 countries.
Target group
Patients with chronic heart failure and iron deficiency.
The problem
Today’s standard treatment requires intravenous injections in hospitals, which is costly and carries risks of serious reactions.
Bio Vito's Solution
SUCCIFER® is the world’s first potential oral treatment for heart failure patients. Pilot studies show a near doubling of ferritin levels and improved iron saturation without side effects.
Optimal Health for Women FE-MININ™
FE-MININ™
Status
Ongoing clinical study (FERITUP) – Results March 2026
Target group
Women of childbearing age, athletes and pregnant women.
The problem
Iron deficiency is the world’s largest nutritional deficiency, affecting over 30% of all women globally. It leads to extreme fatigue, depression and impaired cognitive ability.
Bio Vito's Solution
FE-MININ™ offers fast-acting absorption that provides improved energy and recovery without the stomach problems that 60% of users experience with traditional supplements.
Vitality for men 40+
MAXFERMAN™
Status
Ongoing clinical study (FERMANUP) – Results March 2026
Target group
Men over 40 who are experiencing physical and mental decline.
The problem
A rapidly growing but underdiagnosed group, iron deficiency in men is often mistaken for stress, burnout, or aging.
Bio Vito's Solution
MAXFERMAN™ is specifically designed to counteract sudden periods of fatigue (“Hard-down periods”) by restoring ferritin levels effectively and gently.
Commercial timeline
The path to market approval
Q4 2025
Start of studies for FE-MININ™ and MAXFERMAN™.
Clinical Data Ready
Final clinical reports are completed by Professor Fredrik Nyström .
Value Jump 2026
Expected EFSA approval for all three products and launch in 27 EU countries.